Small extracellular vesicles of hypoxic endothelial cells regulate the therapeutic potential of adipose-derived mesenchymal stem cells via miR-486-5p/PTEN in a limb ischemia model.
Shen Z., Wang W., Chen J., Chen B., Tang Y., Hou J.
Prospective Study on Peripheral Artery Disease, published in J Nanobiotechnology (2022) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- J Nanobiotechnology (2022)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 36153544
- PMCID
- PMC9509557
- DOI
- 10.1186/s12951-022-01632-1
- Citations
- 15
Abstract (original English)
Background Patients with critical limb ischemia (CLI) are at great risk of major amputation and cardiovascular events. Adipose-derived mesenchymal stem cell (ADSC) therapy is a promising therapeutic strategy for CLI, but the poor engraftment and insufficient angiogenic ability of ADSCs limit their regenerative potential. Herein, we explored the potential of human umbilical vein endothelial cells (HUVECs)-derived small extracellular vesicles (sEVs) for enhancing the therapeutic efficacy of ADSCs in CLI. Results sEVs derived from hypoxic HUVECs enhanced the resistance of ADSCs to reactive oxygen species (ROS) and further improved the proangiogenic ability of ADSCs in vitro. We found that the hypoxic environment altered the composition of sEVs from HUVECs and that hypoxia increased the level of miR-486-5p in sEVs. Compared to normoxic sEVs (nsEVs), hypoxic sEVs (hsEVs) of HUVECs significantly downregulated the phosphatase and tensin homolog (PTEN) via direct targeting of miR-486-5p, therefore activating the AKT/MTOR/HIF-1α pathway and influencing the survival and pro-angiogenesis ability of ADSCs. In a hindlimb ischemia model, we discovered that hsEVs-primed ADSCs exhibited superior cell engraftment, and resulted in better angiogenesis and tissue repair. Conclusion hsEVs could be used as a therapeutic booster to improve the curative potential of ADSCs in a limb ischemia model. Thi
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis
Meta-analysis on Peripheral Artery Disease, published in PLoS One (2025) — summary generated from the PubMed abstract.
- 2025
PLoS One1 citations - Level ASystematic ReviewPubMed
The Efficacy of Stem Cells in Wound Healing: A Systematic Review.
Systematic Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci60 citations - Level AMeta-analysisEurope PMC
The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-An
Meta-analysis on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in J Clin Med (2024) — summary generated from the PubMed abstract.
- 2024
J Clin Med2 citations - Level ASystematic ReviewEurope PMC
A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia
Systematic Review on Peripheral Artery Disease, published in J Vasc Surg (2022) — summary generated from the PubMed abstract.
- 2022
J Vasc Surg23 citations - Level AMeta-analysisEurope PMC
Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials
Meta-analysis with a reported sample of 1096 on Peripheral Artery Disease, Chronic Wound, published in Cells (2021) — summary generated from the PubMed abstract.
- 2021
- n = 1096
Cells19 citations - Level ARandomized Controlled TrialPubMed
Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF).
Randomized Controlled Trial with a reported sample of 114 on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
- 2019
- n = 114
Stem Cell Res Ther57 citations